Hypertensive Nephropathy

Hypertensive nephropathy is the second leading cause of end-stage renal disease in the United States, accounting for 25–30% of ESRD cases — surpassed only by diabetic nephropathy. However, the diagnosis carries important complexity: distinguishing true hypertension-driven kidney injury from primary CKD causing secondary hypertension remains one of nephrology's most debated questions. What is clear is that sustained elevated blood pressure damages the kidney's microvasculature, and that APOL1 gene variants in patients of West African ancestry dramatically amplify this risk independent of blood pressure control.

Table of Contents

1. What is Hypertensive Nephropathy?
2. Pathophysiology: How Hypertension Damages the Kidney
3. APOL1 Variants and Racial Disparity
4. Diagnosis
5. Blood Pressure Targets and Treatment
6. The AASK Trial: ACE Inhibitors vs. Calcium Channel Blockers
7. SPRINT Trial: Intensive Blood Pressure Control in CKD
8. Malignant Hypertensive Nephrosclerosis
9. Progression to ESRD and Dialysis Planning
10. Research Papers
11. Connections
12. Featured Videos

What is Hypertensive Nephropathy?

Hypertensive nephropathy — also called hypertensive kidney disease or hypertensive nephrosclerosis — refers to chronic kidney injury attributed to sustained high blood pressure. It is the second most common attributed cause of end-stage renal disease (ESRD) in the United States, responsible for roughly 25–30% of new dialysis patients each year, trailing only diabetic nephropathy.

Yet the diagnosis comes with a fundamental tension that nephrologists continue to debate: the chicken-and-egg problem. High blood pressure damages the kidneys — but damaged kidneys also raise blood pressure. When a patient arrives with both longstanding hypertension and CKD, which came first? Biopsy studies have repeatedly shown that a meaningful proportion of patients clinically labeled "hypertensive nephropathy" actually have primary glomerular or tubulointerstitial disease as the initiating event, with hypertension developing secondarily. Without a biopsy — which is rarely performed in routine hypertensive CKD — the attributional question cannot be definitively answered. This does not mean the diagnosis is wrong, but it does mean that hypertensive nephropathy is partly a clinical construct, and treatment of blood pressure is justified regardless of which came first.

The strongest demographic risk factor for hypertensive ESRD is African American race. African Americans develop hypertension-associated ESRD at rates 3–4 times higher than white Americans, even when blood pressure levels are similar. Much of this disparity traces to APOL1 gene variants that are common in people of West African ancestry — a genetic susceptibility, not a difference in medication adherence or access to care.

Back to Table of Contents

Pathophysiology: How Hypertension Damages the Kidney

The kidney's filtration units — glomeruli — are exquisitely sensitive to pressure. Sustained elevated blood pressure sets off a cascade of microvascular injury that, over years and decades, progressively destroys functioning nephrons.

Endothelial Dysfunction and Arteriolar Injury

The process begins in the smallest vessels. Chronic high pressure induces endothelial dysfunction: the cells lining arterioles reduce nitric oxide production, become pro-inflammatory, and lose their ability to buffer pressure fluctuations. The afferent arterioles — which bring blood into the glomeruli — are particularly vulnerable. Over time, their smooth muscle cells are progressively replaced by protein deposits (proteinaceous material), a process called arteriolar hyalinosis. This is the hallmark biopsy finding of benign nephrosclerosis (the chronic, slowly progressive form of hypertensive kidney injury).

Simultaneously, the larger interlobular arteries develop intimal thickening and fibrosis, further narrowing the vascular lumen and reducing renal blood flow to downstream glomeruli.

Glomerular Ischemia and Scarring

Reduced blood flow through narrowed arterioles causes glomerular ischemia. Ischemic glomeruli first shrink and wrinkle (ischemic collapse), then scar — a process called glomerulosclerosis. This often takes the pattern of focal segmental glomerulosclerosis (FSGS), which is why FSGS on biopsy does not always mean primary FSGS disease; it can be the scar pattern of hypertensive or other secondary injury.

Surviving nephrons compensate by hyperfiltrating — increasing their individual filtration rate to maintain total kidney function. This compensation is beneficial in the short term but harmful over time, because glomerular hypertension in the remaining nephrons accelerates their own injury, creating a self-sustaining cycle of nephron loss.

Tubulointerstitial Fibrosis

Ischemia and the inflammatory mediators released during glomerular injury spread to the surrounding tubules and interstitium. Tubular atrophy (shrinkage of tubular cells) and interstitial fibrosis (replacement of normal kidney tissue with collagen) are the histological hallmarks of advanced CKD regardless of cause, and they are seen prominently in hypertensive nephropathy. Fibrosis correlates closely with GFR loss and is largely irreversible.

RAAS Activation: Victim Becomes Perpetuator

As renal blood flow falls, the juxtaglomerular apparatus senses reduced perfusion and releases renin, activating the renin-angiotensin-aldosterone system (RAAS). Angiotensin II raises systemic blood pressure (worsening the hypertension that caused the injury) and constricts the efferent arteriole (raising intraglomerular pressure). Aldosterone causes sodium and water retention (further raising blood pressure). The kidney, damaged by hypertension, responds in ways that perpetuate and worsen that very hypertension — which explains why ACE inhibitors and ARBs, which block this RAAS feedback loop, are so critical in hypertensive CKD.

Back to Table of Contents

APOL1 Variants and Racial Disparity

One of the most important discoveries in nephrology genetics over the past two decades is the identification of APOL1 risk variants — gene variants that explain much of the racial disparity in hypertension-associated kidney failure.

What Are APOL1 Risk Alleles?

APOL1 (apolipoprotein L1) is a gene on chromosome 22 that encodes a protein involved in innate immunity — specifically in lysing the trypanosome parasites that cause African sleeping sickness. Two variant alleles, called G1 and G2, arose in West Africa because they confer resistance to Trypanosoma brucei rhodesiense. This evolutionary advantage meant that people carrying G1 or G2 survived parasitic disease at higher rates — but the same variants, it turns out, predispose to kidney disease.

Approximately 13% of African Americans carry two APOL1 risk alleles (homozygous or compound heterozygous for G1/G2) — a "two-hit" genotype that confers substantially elevated kidney disease risk. The majority of people of West African ancestry carry zero or one risk allele, and those individuals appear to have kidney risk similar to the general population.

Magnitude of Risk

African Americans with the high-risk APOL1 genotype (two risk alleles) have a 3–4 times higher rate of hypertension-attributed ESRD compared to white Americans, even when blood pressure levels and treatment are comparable. They also progress faster to ESRD once CKD is present, and they have higher rates of FSGS on biopsy. This disparity cannot be explained by access to care, medication adherence, or blood pressure control alone — the genetic contribution is substantial and independent.

Mechanism of APOL1-Mediated Injury

The mechanism is not fully understood but involves APOL1 protein expression in podocytes (the glomerular epithelial cells that maintain the filtration barrier). Normally, APOL1 expression in the kidney is low. In the presence of inflammatory triggers — particularly interferon signaling from viral infections (HIV, CMV, parvovirus B19) or systemic inflammation — APOL1 expression is upregulated sharply in podocytes, and the G1/G2 protein variants appear to be toxic to these cells in high concentrations. This "two-hit" model (genetic susceptibility + environmental trigger) explains why many APOL1 high-risk individuals maintain normal kidney function for decades, then experience rapid decline after an infection or inflammatory event.

Clinical Implications

For patients of West African ancestry with hypertensive CKD, knowing the APOL1 genotype has practical implications: it explains why their kidney disease may progress faster than expected despite apparently well-controlled blood pressure, and it should prompt more aggressive monitoring, earlier nephrology referral, and earlier discussion of transplant planning. Importantly, this is a genetic predisposition — not a consequence of non-adherence or lifestyle. Clinicians should be careful not to frame the racial disparity in kidney outcomes as a failure of individual patients.

APOL1 testing is now commercially available, and there is active research into therapies that directly target APOL1 protein function (including APOL1 inhibitors in clinical trials as of 2023–2025).

Back to Table of Contents

Diagnosis

Hypertensive nephropathy is largely a diagnosis of exclusion. There is no single test that confirms it; rather, the diagnosis is made by accumulating evidence consistent with hypertensive injury while ruling out other causes of CKD.

Clinical Criteria Suggesting Hypertensive Nephropathy

• Long-standing hypertension predating CKD: Hypertension present for 5–10 or more years before the onset of measurable kidney injury is a key clue. If CKD appeared before or simultaneously with hypertension, other causes are more likely.
• Mild proteinuria: Hypertensive nephropathy typically causes tubulointerstitial rather than glomerular injury, so proteinuria is usually modest — less than 1 g per 24 hours, often less than 0.5 g. Heavy proteinuria (>3 g/day, nephrotic-range) strongly suggests a primary glomerular disease rather than simple hypertensive injury.
• Small, echogenic kidneys bilaterally: Renal ultrasound showing bilaterally small, echogenic kidneys (reflecting fibrosis) is consistent with chronic hypertensive or any other chronic kidney disease. Asymmetric kidneys raise the possibility of renovascular hypertension.
• Bland urinalysis: Urine microscopy showing few cells and at most scattered granular casts — not red cell casts (which suggest active glomerulonephritis) or heavy pyuria (which suggests interstitial nephritis or infection).
• Absence of features pointing to other diagnoses: No heavy proteinuria, no hematuria suggesting glomerulonephritis, no family history of ADPKD, no signs of systemic lupus, no paraprotein on serum electrophoresis, no diabetic retinopathy to support diabetic nephropathy.

Key Diagnostic Tests

• Urine albumin-to-creatinine ratio (UACR): The standard screening test. Normal is <30 mg/g; microalbuminuria is 30–300 mg/g; macroalbuminuria is >300 mg/g. In hypertensive nephropathy, UACR is typically in the microalbuminuric range. UACR >300 mg/g (macroalbuminuria) is more typical of diabetic nephropathy or primary glomerular disease.
• eGFR (CKD-EPI equation): The 2021 CKD-EPI creatinine-cystatin C equation is the current standard; importantly, the race coefficient was removed from the creatinine-only equation in 2021 based on evidence that it was not biologically justified and led to underestimation of CKD severity in Black patients.
• Urinalysis and microscopy: Look for proteinuria (dipstick), red cells, white cells, and casts. A bland sediment with mild proteinuria fits hypertensive nephropathy; active sediment suggests an alternative diagnosis.
• Renal biopsy: Rarely performed in routine hypertensive CKD because the diagnosis is clinical. Biopsy is indicated when proteinuria is heavier than expected, when the rate of progression is faster than expected, or when clinical features suggest an alternative diagnosis (e.g., possible lupus nephritis, rapidly progressive GFR loss). Biopsy findings in hypertensive nephropathy: arteriolar hyalinosis + FSGS pattern of glomerulosclerosis + tubular atrophy + interstitial fibrosis.

Back to Table of Contents

Blood Pressure Targets and Treatment

Lowering blood pressure is the most important intervention in hypertensive nephropathy — but the choice of drug matters beyond just achieving the target number, and the right target itself has been debated across major clinical trials.

Current Guideline Targets

The 2017 ACC/AHA hypertension guidelines and the 2021 KDIGO CKD guidelines both recommend a target blood pressure of <130/80 mmHg for patients with CKD, including those with hypertensive nephropathy. This is a tighter target than the older JNC7 target of <130/80 for high-risk and <140/90 for general CKD. The rationale is that lower BP reduces both cardiovascular events and the rate of kidney function decline.

ACE Inhibitors and ARBs: First-Line in Proteinuric CKD

For patients with CKD and proteinuria (>300 mg/g albumin-creatinine ratio), ACE inhibitors (ramipril, lisinopril, enalapril) or ARBs (losartan, valsartan, irbesartan) are the preferred first-line agents. Their benefit goes beyond blood pressure lowering:

• By blocking angiotensin II, they dilate the efferent arteriole (as well as the afferent), reducing intraglomerular pressure and thus the mechanical stress on the filtration barrier.
• They reduce proteinuria independently of BP lowering — this reduction in proteinuria itself slows CKD progression.
• They blunt RAAS-mediated renal fibrosis.

An important caution: do not combine an ACE inhibitor with an ARB (dual RAAS blockade). The ONTARGET trial showed that telmisartan plus ramipril provided no additional cardiovascular benefit over ramipril alone but substantially increased the rates of hyperkalemia, hypotension, and acute kidney injury. Dual RAAS blockade is contraindicated.

A serum creatinine rise of up to 30% after starting an ACE inhibitor or ARB is expected and acceptable (it reflects efferent dilation reducing filtration pressure, not drug-induced kidney damage) — this rise should not prompt drug discontinuation unless it exceeds 30% or is accompanied by hyperkalemia.

Second-Line Agents

• Dihydropyridine calcium channel blockers (amlodipine): Excellent add-on antihypertensive for CKD; nephroprotective when combined with an ACE inhibitor or ARB. Note: used alone (without RAAS blockade) in proteinuric CKD, CCBs do not reduce proteinuria as effectively.
• Thiazide-like diuretics: Chlorthalidone is preferred over hydrochlorothiazide (longer half-life, greater BP reduction, cardiovascular outcome data). Effective in CKD stages 1–3; in advanced CKD (eGFR <30), loop diuretics (furosemide) may be needed instead.
• Aldosterone antagonists (spironolactone, eplerenone): Useful for resistant hypertension (BP not controlled on 3 agents) in CKD. Requires careful potassium monitoring due to hyperkalemia risk, especially when combined with ACE inhibitors or ARBs.

What to Avoid

• NSAIDs: All non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, indomethacin, ketorolac) constrict the afferent arteriole, raising intraglomerular pressure, worsening blood pressure, and precipitating acute-on-chronic kidney injury. Even over-the-counter dosing matters in CKD.
• Dietary sodium excess: High sodium intake raises blood pressure, blunts the antiproteinuric effect of ACE inhibitors/ARBs, and promotes fluid retention. A target of <2 g sodium per day (<5 g salt) is recommended for CKD patients.
• Nephrotoxins: IV contrast (use pre-hydration and minimum volume when essential), aminoglycoside antibiotics, and herbal nephrotoxins (aristolochic acid in some traditional herbal preparations) warrant particular caution.

Back to Table of Contents

The AASK Trial: ACE Inhibitors vs. Calcium Channel Blockers

The African American Study of Kidney Disease and Hypertension (AASK) is the landmark trial that established ACE inhibitors as the preferred treatment for hypertensive CKD in African American patients — a group at disproportionately high risk for ESRD.

Design

AASK enrolled 1,094 African Americans aged 18–70 with hypertension and CKD (GFR 20–65 mL/min per 1.73 m²), and no proteinuria heavy enough to suggest primary glomerular disease. Participants were randomized in a 3×2 factorial design: three antihypertensive drug classes (ramipril, an ACE inhibitor; metoprolol, a beta-blocker; amlodipine, a calcium channel blocker) crossed with two blood pressure targets (standard: mean arterial pressure 102–107 mmHg, vs. lower: MAP <92 mmHg). Follow-up averaged 4 years.

Results

The amlodipine arm was stopped early due to a significantly higher rate of the primary composite endpoint (50% GFR reduction, ESRD, or death) compared to ramipril. Ramipril was superior to both amlodipine and metoprolol for slowing GFR decline and reducing the composite outcome. The drug class effect was stronger than the blood pressure target effect — meaning which drug you used mattered more than how low you drove the blood pressure (within the tested range).

This established ACE inhibitors (and by extension ARBs) as the cornerstone of treatment for African American patients with hypertensive CKD. Calcium channel blockers remain valuable as add-on therapy but should not be used as single-agent first-line therapy in proteinuric hypertensive CKD.

APOL1 Sub-Analysis (Parsa 2013)

A landmark genetic sub-study of AASK participants found that patients with the high-risk APOL1 genotype (two risk alleles) had faster progression to ESRD regardless of which blood pressure treatment arm they were assigned to. The genetic effect on progression was independent of — and larger than — the treatment arm effect. This finding fundamentally changed the understanding of racial disparity in hypertensive CKD: it is not primarily about blood pressure control failing in African American patients, but about an underlying genetic amplifier of kidney injury that treatment alone cannot fully overcome.

Back to Table of Contents

SPRINT Trial: Intensive Blood Pressure Control in CKD

The Systolic Blood Pressure Intervention Trial (SPRINT), published in 2015, addressed a question that AASK did not fully answer: in patients with CKD but without diabetes, does intensive BP control (targeting SBP <120 mmHg) provide additional benefit over standard control (SBP <140 mmHg)?

Design

SPRINT enrolled 9,361 patients aged 50 or older with SBP 130–180 mmHg and at least one additional cardiovascular risk factor. Patients with diabetes or prior stroke were excluded. The CKD subgroup — defined as eGFR 20–59 mL/min per 1.73 m² — comprised approximately 28% of participants (about 2,600 patients), making it one of the largest hypertensive CKD treatment trials.

Results in the CKD Subgroup

• Cardiovascular events: Intensive BP control reduced the primary cardiovascular composite (MI, other acute coronary syndrome, stroke, acute decompensated heart failure, cardiovascular death) significantly in the overall trial and also in the CKD subgroup.
• Kidney function: The CKD subgroup showed numerically slower eGFR decline with intensive control, though this did not reach statistical significance as a primary endpoint. Rates of ESRD were too low during the follow-up period to draw definitive conclusions.
• Acute kidney injury events: Intensive BP control was associated with a roughly 3-fold higher rate of AKI events (serum creatinine increases meeting AKI criteria) in the CKD subgroup. Most were transient and not associated with permanent loss of kidney function, but this signal requires clinical attention.

Clinical Application

SPRINT supports targeting SBP <120 mmHg in patients with hypertensive CKD who can tolerate it, primarily for cardiovascular risk reduction. The 2021 KDIGO blood pressure guidelines adopted a target of SBP <120 mmHg for high-risk patients "if tolerated" — a nuanced recommendation that recognizes the AKI risk and the need for individualization.

In practice: younger patients with proteinuric CKD and high cardiovascular risk benefit most from intensive targets. Elderly or frail patients, patients with orthostatic hypotension, and those at high fall risk should have standard targets (<130–140 mmHg SBP). The intensive target requires more frequent monitoring of electrolytes and renal function after any medication change.

Back to Table of Contents

Malignant Hypertensive Nephrosclerosis

While most hypertensive nephropathy evolves slowly over years or decades, a minority of patients develop malignant (accelerated) hypertension — a medical emergency in which severely elevated blood pressure causes rapid, life-threatening end-organ damage, including acute kidney injury that can be dramatic.

Definition and Presentation

Malignant hypertension is defined as BP typically >180/120 mmHg with evidence of acute end-organ damage. The specific organs affected define the clinical emergency:

• Eyes: Hypertensive retinopathy with papilledema (swelling of the optic disc from elevated intracranial pressure) — the defining feature historically. Flame hemorrhages, cotton-wool spots, arteriovenous nicking.
• Brain: Hypertensive encephalopathy (confusion, visual disturbance, headache, seizures) or hemorrhagic/ischemic stroke.
• Kidneys: Rapid acute kidney injury — creatinine may rise by several mg/dL over days. Urinalysis may show proteinuria, hematuria, and red cell or granular casts from glomerular injury.
• Heart: Acute decompensated heart failure, pulmonary edema from acutely elevated afterload, acute aortic dissection.

Pathology: Fibrinoid Necrosis and TMA

The kidney biopsy in malignant hypertensive nephrosclerosis shows a distinctly different picture from benign nephrosclerosis. Rather than arteriolar hyalinosis, there is fibrinoid necrosis — the arteriolar walls are replaced by eosinophilic fibrin-like material with inflammatory cell infiltration — and a pattern of thrombotic microangiopathy (TMA): fibrin thrombi in glomerular capillaries and arterioles, similar to what is seen in hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). This is why severe malignant hypertension can cause microangiopathic hemolytic anemia and thrombocytopenia in addition to AKI — a presentation that must be distinguished from primary TMA diseases.

Emergency Treatment

The management of malignant hypertension requires careful, controlled reduction of blood pressure — not rapid normalization. Auto-regulation of cerebral and coronary blood flow is reset at the chronically elevated level; rapid normalization risks ischemia in these organs.

• Reduce mean arterial pressure by approximately 10–15% in the first hour, then by no more than 25% over 2–6 hours.
• Then allow a more gradual reduction to near-normal levels over 24–48 hours.
• Intravenous agents used in the ICU setting: labetalol (combined alpha/beta blocker; preferred in most hypertensive emergencies), nicardipine (calcium channel blocker infusion), clevidipine (ultrashort-acting CCB), sodium nitroprusside (for short-term use only — cyanide toxicity limits duration; requires arterial line monitoring).
• Once stabilized, transition to oral agents (ACE inhibitor or ARB as first-line).

Renal Prognosis

With prompt, controlled BP reduction, some degree of kidney recovery is possible even in patients with severe acute kidney injury from malignant hypertension. Some patients will remain dialysis-dependent; others may experience partial or even substantial recovery over weeks to months. Early, aggressive treatment is critical — delay results in permanent glomerular and arteriolar destruction.

Back to Table of Contents

Progression to ESRD and Dialysis Planning

Not all patients with hypertensive nephropathy progress to end-stage renal disease, but those who do face a years-long transition that requires proactive planning. Early preparation substantially improves quality of life and survival outcomes.

Risk Factors for Faster Progression

• APOL1 high-risk genotype — the strongest genetic predictor in patients of West African ancestry
• Baseline proteinuria >0.5 g/day — even modest proteinuria accelerates progression; proteinuria >1 g/day substantially increases risk
• Poorly controlled blood pressure — each 10 mmHg reduction in SBP reduces CKD progression risk by approximately 15–20%
• Concurrent diabetes — diabetic and hypertensive injury are synergistic
• Older age at diagnosis — less renal reserve
• Black race — reflecting both APOL1 biology and societal factors affecting chronic disease management

Monitoring Schedule

For patients with hypertensive CKD, standard monitoring includes: eGFR and UACR at minimum annually (more frequently as CKD advances); serum potassium (especially on ACE inhibitors or ARBs — hyperkalemia is a major dose-limiting side effect); phosphate (rises as GFR falls, contributing to mineral bone disease); hemoglobin (renal anemia from reduced erythropoietin production); calcium and parathyroid hormone (CKD-related mineral bone disease).

Managing CKD Complications

• Renal anemia: When hemoglobin falls below 10 g/dL, erythropoiesis-stimulating agents (ESAs: epoetin alfa, darbepoetin) may be initiated, along with iron supplementation (iron deficiency is common and limits ESA response).
• CKD-mineral bone disease (CKD-MBD): Phosphate binders (calcium carbonate, sevelamer) reduce GI phosphate absorption; active vitamin D analogues (calcitriol, paricalcitol) supplement reduced renal vitamin D activation and suppress secondary hyperparathyroidism.
• Metabolic acidosis: Oral sodium bicarbonate supplementation when serum bicarbonate is below 22 mEq/L has been shown to slow CKD progression in some trials.

Planning for Renal Replacement Therapy

When eGFR falls to approximately 15–20 mL/min per 1.73 m², it is time to begin preparing for renal replacement therapy — not to start it yet, but to ensure the patient has good options when the time comes:

• Arteriovenous fistula creation: If hemodialysis is the intended modality, an AV fistula (the preferred vascular access) takes 6 or more months to mature. Creating it too late forces reliance on central venous catheters, which carry infection risk and worse outcomes. Referral to vascular surgery should occur when eGFR is in the 15–25 range.
• Kidney transplant evaluation: Transplant is the best long-term outcome for eligible patients. Pre-emptive transplant (before starting dialysis) is associated with better graft and patient survival than transplant after dialysis initiation. Transplant workup should begin early — ideally when eGFR is 20–25.
• Peritoneal dialysis: A home-based alternative to hemodialysis; requires intact peritoneum and patient motivation. Generally achieves equivalent outcomes to in-center hemodialysis in the early years.
• Conservative management: For elderly patients or those with significant comorbidities who opt not to pursue dialysis, a conservative (non-dialytic) management pathway focused on symptom control and quality of life is a legitimate and dignified choice. Survival on dialysis in elderly patients with multiple comorbidities may be no better than conservative management, and the burden of treatment is substantial.

Back to Table of Contents

Research Papers

1. Wright JT Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288(19):2421–2431. PMID: 12435255
2. Appel LJ et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–929. PMID: 20818902
3. Parsa A et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183–2196. PMID: 24206458
4. Freedman BI et al. APOL1 and kidney disease in African Americans. J Am Soc Nephrol. 2014;25(3):516–523. PMID: 24436468
5. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. PMID: 26551272
6. Cheung AK et al. Effects of intensive blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2017;28(9):2812–2823. PMID: 28642330
7. Yusuf S et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). N Engl J Med. 2008;358(15):1547–1559. PMID: 18378520
8. Whelton PK et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248. PMID: 29146535
9. Inker LA et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. PMID: 34554658
10. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44(5):595–601. PMID: 15466643
11. Klag MJ et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–18. PMID: 7494561
12. Kaplan NM. Hypertensive nephrosclerosis: a frequently misunderstood entity. Am J Nephrol. 2015;42(2):93–96. PMID: 26422823

Back to Table of Contents

Connections

• Chronic Kidney Disease
• Diabetic Nephropathy
• Focal Segmental Glomerulosclerosis
• Glomerulonephritis
• Acute Kidney Injury
• Polycystic Kidney Disease
• IgA Nephropathy
• Hypertension
• Potassium
• Creatinine

Back to Table of Contents

Featured Videos